Systemic Light Chain Amyloidosis – Version 1.2016

This is a clinical practice guideline for the diagnosis and management of systemic light chain amyloidosis. Primary systemic light chain amyloidosis is typically characterized by decreased numbers of monoclonal plasma cells in the bone marrow compared to multiple myeloma, however, the protein produced by these plasma cells has an affinity for visceral organs (such as kidney, heart, liver, and spleen), and this protein causes related end-organ dysfunction. Recommendations include a discussion of the management options such as transplant and chemotherapy.